ArteryFlow Technology

As a leader in intelligent diagnosis and treatment of cardiovascular and cerebrovascular diseases, Hangzhou ArteryFlow Technology Co., Ltd., headquartered in Hangzhou, is an innovative technology company that provides precise and personalized diagnosis and treatment for cardiovascular and cerebrovascular diseases based on medical big data technology, computational simulation technology, and artificial intelligence algorithms. The core R&D team consists of doctors and masters graduated from world-class universities such as MIT and Imperial College London, with more than ten years of R&D experience in computational simulation, deep learning, and image processing. The company offers comprehensive solutions for cardiovascular and cerebrovascular diseases, with products covering intelligent screening, detection, diagnosis, and surgical planning for such conditions. Among them, the three major products for coronary functional assessment—AccuFFRct, AccuFFRangio, and AccuFFRivus—as well as the AI ECG recognition system DeepECG have entered clinical application. The seven major case systems jointly developed by ArteryFlow and CTO Lao Huo Ji can record and share cardiac surgery cases anytime, anywhere. Relying on the ArteryFlow cloud platform, ArteryFlow Technology provides precise and personalized diagnostic services for cardiovascular and cerebrovascular diseases to hospitals, imaging centers, health examination institutions, and patients, offering better diagnostic and treatment experiences for both patients and clinicians.